pyrvinium has been researched along with Carcinoma, Pancreatic Ductal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowne, WB; Brody, JR; Cannaday, S; Lavu, H; Leiby, BE; Nevler, A; Ponzini, FM; Posey, J; Schultz, CW; Yeo, C; Yeo, T | 1 |
| Baechler, SA; Brody, JR; Brown, SZ; Calvert, VS; Cassel, J; Dixon, DA; DuHadaway, JB; Goetz, A; Golan, T; Jain, A; Jiang, W; McCarthy, GA; McCoy, MD; Nerwal, T; Nevler, A; Petricoin, EF; Pishvaian, MJ; Pommier, Y; Preet, R; Prendergast, GC; Salvino, J; Schultz, CW; Shaghaghi, H; Singh, PK; Summer, R; Vishwakarma, V; Wang, D; Yeo, CJ | 1 |
1 trial(s) available for pyrvinium and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Anthelmintics; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase I as Topic; Drug Repositioning; Humans; Pancreatic Neoplasms | 2023 |
1 other study(ies) available for pyrvinium and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
Topics: Adenocarcinoma; Animals; Anthelmintics; Carcinoma, Pancreatic Ductal; Humans; Metabolomics; Mice; Pyrvinium Compounds; Survival Analysis; United States; United States Food and Drug Administration | 2021 |